India's cost-effective pharma model attracts global giants amid start-up surge

Even as major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential, the Indian government's initiatives to foster the growth of start-ups in the pharmaceutical sector appears to be further catalyzing the trend.

Start-ups in the Indian pharma sector have soared from 283 in 2021 to the current 1,397, underscoring the entrepreneurial spirit and innovative potential within the industry, reports The Pharma Letter’s India correspondent.

By providing a supportive ecosystem for innovation, the government's initiatives are creating a fertile ground for collaboration between domestic companies and multinational partners, said an official, accelerating drug discovery, and market access.